Point72 Europe’s ACELYRIN SLRN Stock Holding History

Point72 Europe’s Portfolio SLRN Stock Details SLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-122,971	Closed	-$917K	–	390
2023 Q4	$917K	Buy	+122,971	New	+$1.05M	0.11%	113

Other funds holding SLRN

ACMC

AyurMaya Capital Management Company Portsmouth, New Hampshire $148M AUM 24.4% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

TCM

Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return

Point72 Europe's SLRN Position: Q1 2024 in Review

Point72 Europe sold out of ACELYRIN (SLRN) in Q1 2024, closing a stake of 122,971 shares — an estimated $917K sold.

Point72 Europe first reported a position in SLRN in Q4 2023 and held it in 1 quarter. The position peaked at $917K in Q4 2023. 109 funds tracked by Wall St. Rank hold SLRN as of Q1 2024.

Point72 Europe reported no remaining ACELYRIN position as of Q1 2024 after selling out during the quarter.
Point72 Europe sold 122,971 ACELYRIN shares in Q1 2024, an estimated $917K.
Point72 Europe first reported a position in ACELYRIN in Q4 2023 and held it in 1 quarter.
Point72 Europe's ACELYRIN position peaked at $917K in Q4 2023.
109 funds tracked by Wall St. Rank held ACELYRIN as of Q1 2024.

Based on Point72 Europe's 13F filing for Q1 2024, filed 15 May 2024.